People working for the Dr. Bronner\u2019s Magic Soaps company are now able to access psychedelic-assisted treatment as part of a healthcare benefits expansion that aligns with the pro-reform goals of the company\u2019s CEO David Bronner.<\/p>\n
On Monday, Dr. Bronner\u2019s announced the partnership with the non-profit healthcare organization Enthea, which specializes in ketamine-assisted therapy. Experts view ketamine as an effective treatment option for conditions such as treatment-resistant depression and post-traumatic stress disorder.<\/p>\n
\u201cWe strive to effect positive change in all our spheres of influence. The well-being of our employees is paramount to our company culture,\u201d Bronner said<\/a> in a press release. \u201cWe also know from experience that offering strong benefits helps with employee retention and recruitment.\u201d<\/p>\n \u201cWe hope to inspire and be a model for other companies and organizations to also partner with Enthea and offer this potentially lifesaving benefit to their staff,\u201d he said.<\/p>\n Dr. Bronner’s now offers free ketamine-assisted therapy to all benefit-eligible employees to support their mental health.<\/p>\n “Considering all our advocacy on this issue, this employee benefit is the next logical step.” \u2014Mike Bronner @nytimes<\/a> https:\/\/t.co\/Rl6Oo0u6bE<\/a><\/p>\n \u2014 Dr. Bronner’s (@DrBronner) February 28, 2022<\/a><\/p>\n<\/blockquote>\n\n The partnership makes sense, given that Bronner and the company have invested in numerous drug policy reform initiatives across the country. He provided a significant financial contribution<\/a> to the successful 2020 campaign to make Oregon the first state in the U.S. to legalize psilocybin therapy, for example.<\/p>\n \u201cThe health and well-being of our employees is the primary driver in how we think about benefits and compensation,\u201d Michael Bronner, president of Dr. Bronner\u2019s, said in a press release. \u201cOffering coverage for Ketamine Assisted Therapy is in the interest of providing tools to our workforce to have the best quality of life and best options for mental health care.\u201d<\/p>\n \u201cOur family and company are no strangers to depression and anxiety. We are deeply concerned about the mental health crisis society is facing, especially in the context of the Covid-19 pandemic,\u201d he said. \u201cConsidering all our advocacy on this issue, this employee benefit is the next logical step.\u201d<\/p>\n Ketamine has been approved by the Food and Drug Administration (FDA) for us as an anesthetic and is not currently specifically approved for any psychiatric disorders, though doctors are able to administer it for off-label purposes like they can with other pharmaceuticals. There is also an FDA-approved nasal spray called esketamine that produces similar effects and is authorized for the treatment of treatment-resistant depression and is accordingly classified under Schedule III.<\/p>\n There are ketamine clinics operating in states from Alabama to Washington, but not all insurance companies cover the treatment.<\/p>\n Dr. Bronner\u2019s began including ketamine therapy in its healthcare package on January 1 of this year. Enthea also plans to expand its psychedelics treatment toolbox to include MDMA and psilocybin pending the substances\u2019 approval by FDA.<\/p>\n We\u2019re proud to partner with Enthea to become one of the first companies in the U.S. to offer ketamine-assisted therapy as an employee benefit.<\/p>\n Thank you to Andrew Jacobs at the @nytimes<\/a> for sharing our story!<\/p>\n \u2014 Dr. Bronner’s (@DrBronner) February 28, 2022<\/a><\/p>\n<\/blockquote>\n\n \u201cWe are particularly proud of this unique partnership and we applaud Dr. Bronner\u2019s for showing the way for other companies,\u201d Lia Mix, CEO of Enthea, said. \u201cPsychedelic Assisted Therapy holds tremendous promise for addressing our society\u2019s mental health crisis and improving workforce well-being.\u201d<\/p>\n \u201cHigh-performing and forward-thinking companies know the importance of employee mental health,\u201d Mix said. \u201cWe also see the best talent attracted to companies with next-generation benefits like the one implemented by Dr. Bronner\u2019s. We anticipate both human and financial return on these organizations\u2019 investment in covering psychedelic healthcare.\u201d<\/p>\n Dan Rome, chief medical officer at Enthea, said that the \u201ceffectiveness of Ketamine Assisted Therapy has been demonstrated through multiple research studies and more than twenty years of accumulated clinical experience.\u201d<\/p>\n \u201cNumerous studies show that, among individuals with chronic health conditions, those who also suffer from mental health disorders are two to three times more costly to the healthcare system than those without,\u201d he said. \u201cOur society is in dire need of more effective treatments for mental health conditions, to reduce human suffering as well as the economic toll on our overburdened health care system.\u201d<\/p>\n The heads of FDA and the National Institutes of Health (NIH) coauthored a letter in 2019 describing the status of research into psychedelic drugs<\/a>, saying that substances like ketamine, MDMA, psilocybin and ibogaine present an \u201copportunity to provide treatment to patients while expanding psychotherapy treatment options.\u201d<\/p>\n National Institute on Drug Abuse (NIDA) Director Nora Volkow said last year that existing research on the benefits of ketamine for treatment-resistant depression has been an \u201ceye opener\u201d and that more studies are on the way. \u201cWe have been funding research that is ongoing\u2014on ketamine for opiate treatment and also ketamine for pain,\u201d she said.<\/p>\n \u201cWe need to learn from what what the evidence is showing us,\u201d she added. \u201cIf we can use ketamine for the treatment of severe depression in a way that is safe, this is an example of really that we can use drugs that we thought were dangerous and use them in ways that are therapeutic.\u201d<\/p>\n South Dakota House Panel Rejects Senate-Passed Marijuana Legalization Bill While Gutting Medical Cannabis Protections<\/a><\/p>\n<\/blockquote>\n\n Photo courtesy of Wikimedia\/Psychonaught<\/a>.<\/em><\/p>\n The post Soap Company Dr. Bronner\u2019s Offers Psychedelic Treatment To Workers As Part Of Healthcare Benefits Expansion<\/a> appeared first on Marijuana Moment<\/a>.<\/p>\n
People working for the Dr. Bronner\u2019s Magic Soaps company are now able to access psychedelic-assisted treatment as part of a healthcare benefits expansion that aligns with the pro-reform goals of the company\u2019s CEO David Bronner. On Monday, Dr. Bronner\u2019s announced the partnership with the non-profit healthcare organization Enthea, which specializesContinue Reading<\/a><\/span><\/p>\n","protected":false},"author":458,"featured_media":0,"comment_status":"false","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1335],"tags":[],"_links":{"self":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/53221"}],"collection":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/users\/458"}],"replies":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/comments?post=53221"}],"version-history":[{"count":1,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/53221\/revisions"}],"predecessor-version":[{"id":53222,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/53221\/revisions\/53222"}],"wp:attachment":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/media?parent=53221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/categories?post=53221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/tags?post=53221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\n
\n
\nRead More: Soap Company Dr. Bronner\u2019s Offers Psychedelic Treatment To Workers As Part Of Healthcare Benefits Expansion<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"